Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival

Singh, Navneet; Mootha, Vamsi; Madan, Karan; Aggarwal, Ashutosh; Behera, Digambar
September 2013
Medical Oncology;Sep2013, Vol. 30 Issue 3, p1
Academic Journal
No abstract available.


Related Articles

  • Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Du, Gangjun; Yang, Yingming; Zhang, Yaping; Sun, Ting; Liu, Weijie; Wang, Yingying; Li, Jiahuan; Zhang, Houyun // Cancer Chemotherapy & Pharmacology;Apr2013, Vol. 71 Issue 4, p893 

    Purpose: Patients with advanced non-small-cell lung cancer (NSCLC) have poor survival, and platinum-based chemotherapy agents are the standard first-line chemotherapy agents for advanced NSCLC. This study aimed to identify predictive factors associated with the response to chemotherapy and...

  • Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy. Bala, Stalin; Gundeti, Sadashivudu; Linga, Vijay Gandhi; Maddali, Lakshmi Srinivas; Digumarti, Raghunadha Rao; Uppin, Shantveer G. // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2016, Vol. 37 Issue 4, p242 

    Context: Lung cancer is an important cause of cancer-related deaths worldwide. There is an increasing incidence of lung cancer in never smokers and a shift of histology from squamous cell to adenocarcinoma globally in the recent past. Data on treatment outcomes with newer platinum doublets is...

  • Factors affecting 30-month survival in lung cancer patients. Mahesh, P. A.; Archana, S.; Jayaraj, B. S.; Patil, Shekar; Chaya, S. K.; Shashidhar, H. P.; Sunitha, B. S.; Prabhakar, A. K. // Indian Journal of Medical Research;Oct2012, Vol. 136 Issue 4, p614 

    Background & objectives: Age adjusted incidence rate of lung cancer in India ranges from 7.4 to 13.1 per 100,000 among males and 3.9 to 5.8 per 100,000 among females. The factors affecting survival in lung cancer patients in India are not fully understood. The current study was undertaken to...

  • First-line Chemotherapy and Its Survival Analysis of 394 Patients with Extensive-stage Small Cell Lung Cancer in a Single Institute. Manjiao MA; Mengzhao WANG; Yan XU; Ke HU; Huihui LIU; Longyun LI; Wei ZHONG; Li ZHANG; Jing ZHAO; Huazhu WANG // Chinese Journal of Lung Cancer;Jan2014, Vol. 17 Issue 1, p8 

    Background and objective: Small cell lung cancer (SCLC) is the most malignant neuroendocrine tumor but highly sensitive to chemotherapy and radiotherapy. At present, the standard first-line chemotherapy regimen of extensive-stage SCLC is platinum combined etoposide regimen. However, most...

  • Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer. Reiko Yoshino; Hisao Imai; Keita Mori; Yoshio Tomizawa; Kosuke Takei; Mai Tomizawa; Kyoichi Kaira; Akihiro Yoshii; Satoru Watanabe; Ryusei Saito; Masanobu Yamada; Yoshino, Reiko; Imai, Hisao; Mori, Keita; Tomizawa, Yoshio; Takei, Kosuke; Tomizawa, Mai; Kaira, Kyoichi; Yoshii, Akihiro; Watanabe, Satoru // Journal of Cancer Research & Therapeutics;Jul-Sep2015, Vol. 11 Issue 3, p606 

    Introduction: The effects of first-line single-agent chemotherapy on overall survival (OS) might be confounded by subsequent treatments in elderly patients with nonsmall cell lung cancer (NSCLC). We, therefore, aimed to evaluate whether progression-free survival (PFS),...

  • Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature. Dogan, Mutlu; Yalcin, Bulent; Ozdemir, Nuriye; Arslan, Ulku; Dogan, Lutfi; Utkan, Gungor; Akbulut, Hakan; Zengin, Nurullah; Alkis, Necati; Icli, Fikri // Medical Oncology;Sep2012, Vol. 29 Issue 3, p2021 

    Neuroendocrine tumors (NET) are rare, but their incidence is gradually increasing. In this study, demographical and tumor characteristics, treatment modalities, responses, and survival rates were evaluated in the patients with NET. Seventy-one patients with NET from 3 tertiary care centers...

  • Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Kamal, A.; Camacho, F.; Anderson, R.; Wei, W.; Balkrishnan, R.; Kimmick, G. // Breast Cancer Research & Treatment;Oct2012, Vol. 134 Issue 1, p371 

    Capecitabine is often offered as a first-line chemotherapy option for metastatic breast cancer (MBC). In this study, we compare characteristics of and survival among women prescribed first-line capecitabine or taxane monotherapy for MBC. Women receiving first-line chemotherapy for MBC from 1998...

  • Predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall lung cancer patients in China: A retrospective institution analysis of 132 patients. Bin Cheng; Xin-Jun Cai; Ling-Ya Chen; Zeng Wang; Lin Weng; Qing-Lin Li // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC84 

    Objective: To investigate the predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall cell lung cancer (NSCLC) patients in China. Methods: Medical records of 132 patients who underwent chemotherapy from January 2008 to December 2010 in our hospital were...

  • Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. Yoshida, Tatsuya; Ishii, Genichiro; Goto, Koichi; Yoh, Kiyotaka; Niho, Seiji; Umemura, Shigeki; Matsumoto, Shingo; Ohmatsu, Hironobu; Nagai, Kanji; Ohe, Yuichiro; Ochiai, Atsushi // Journal of Cancer Research & Clinical Oncology;Oct2013, Vol. 139 Issue 10, p1691 

    Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) differs in patients with lung adenocarcinoma harboring EGFR-activating mutations. Although lung adenocarcinoma with EGFR-activating mutations has heterogeneous morphologic features, the...

  • Circulating tumor cell level after chemotherapy predicted OS. Altersitz, Katrina; Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p27 

    The article discusses a study led by Jeffrey B. Smerage, which shows that levels of circulating tumor cells after first-line chemotherapy predicted overall survival (OS) among metastatic breast cancer patients, but that changing treatment based on those levels did not change survival or toxicity.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics